Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial of setmelanotide in patients with pro-opiomelanocortin (POMC) deficiency obesity

Next Previous
Trial Profile

A phase III trial of setmelanotide in patients with pro-opiomelanocortin (POMC) deficiency obesity

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Setmelanotide (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Sponsors Rhythm

    • Most Recent Events

    • 04 Nov 2019 According to an Rhythm Pharmaceuticals media release, Dr. Peter Kuhnen is the lead investigator for this trial.
    • 04 Nov 2019 Results published in the Rhythm Pharmaceuticals Media Release.
    • 04 Nov 2019 According to an Rhythm Pharmaceuticals media release, data from this study are being presented in late-breaking research forum during the 37th Annual Meeting of The Obesity Society at ObesityWeek 2019 held, November 3-7, 2019 in Las Vegas.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top